TWi officially launches generic Propafenone HCl ER Capsules in TWi label

August 20 ,2020 . TWi Pharmaceuticals, Inc. (“TWi”) today announced the official launch of Propafenone HCl ER Capsules (equivalent to Rythmol SR®) via its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc.  Product is available for immediate shipment.


Propafenone HCl ER Capsules  are indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. According to IQVIA data, the total sales of Propafenone HCl ER Capsules in the US were approximately US $48 million for the 12 months ended July 2020.



About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier to entry generic prescription products ranging from oral controlled release dosage forms to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit